The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global HIV Therapy Market Research Report 2025
Synopsis
HIV Therapy involves taking a combination of HIV medicines . HIV Therapy is recommended for everyone who has HIV. HIV Therapy cannot cure HIV, but HIV medicines help people with HIV live longer, healthier lives.
The global HIV Therapy market was valued at US$ 3040 million in 2023 and is anticipated to reach US$ 3952.5 million by 2030, witnessing a CAGR of 3.8% during the forecast period 2024-2030.
North American market for HIV Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for HIV Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of HIV Therapy include ViiV Healthcare, Gilead Sciences, Inc., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc. and Genentech, Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for HIV Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HIV Therapy.
Report Scope
The HIV Therapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global HIV Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HIV Therapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
ViiV Healthcare
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Merck Sharp & Dohme Corp.
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH
AbbVie Inc.
Genentech, Inc.
Mylan N.V.
Segment by Type
Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of HIV Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of HIV Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
HIV Therapy involves taking a combination of HIV medicines . HIV Therapy is recommended for everyone who has HIV. HIV Therapy cannot cure HIV, but HIV medicines help people with HIV live longer, healthier lives.
The global HIV Therapy market was valued at US$ 3040 million in 2023 and is anticipated to reach US$ 3952.5 million by 2030, witnessing a CAGR of 3.8% during the forecast period 2024-2030.
North American market for HIV Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for HIV Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of HIV Therapy include ViiV Healthcare, Gilead Sciences, Inc., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc. and Genentech, Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for HIV Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HIV Therapy.
Report Scope
The HIV Therapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global HIV Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HIV Therapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
ViiV Healthcare
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Merck Sharp & Dohme Corp.
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH
AbbVie Inc.
Genentech, Inc.
Mylan N.V.
Segment by Type
Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of HIV Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of HIV Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 HIV Therapy Market Overview
1.1 Product Overview and Scope of HIV Therapy
1.2 HIV Therapy Segment by Type
1.2.1 Global HIV Therapy Market Value Comparison by Type (2024-2030)
1.2.2 Integrase Inhibitors
1.2.3 Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
1.2.4 Combination HIV Medicines
1.2.5 Others
1.3 HIV Therapy Segment by Application
1.3.1 Global HIV Therapy Market Value by Application: (2024-2030)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Global HIV Therapy Market Size Estimates and Forecasts
1.4.1 Global HIV Therapy Revenue 2019-2030
1.4.2 Global HIV Therapy Sales 2019-2030
1.4.3 Global HIV Therapy Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 HIV Therapy Market Competition by Manufacturers
2.1 Global HIV Therapy Sales Market Share by Manufacturers (2019-2024)
2.2 Global HIV Therapy Revenue Market Share by Manufacturers (2019-2024)
2.3 Global HIV Therapy Average Price by Manufacturers (2019-2024)
2.4 Global HIV Therapy Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of HIV Therapy, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of HIV Therapy, Product Type & Application
2.7 HIV Therapy Market Competitive Situation and Trends
2.7.1 HIV Therapy Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest HIV Therapy Players Market Share by Revenue
2.7.3 Global HIV Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 HIV Therapy Retrospective Market Scenario by Region
3.1 Global HIV Therapy Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global HIV Therapy Global HIV Therapy Sales by Region: 2019-2030
3.2.1 Global HIV Therapy Sales by Region: 2019-2024
3.2.2 Global HIV Therapy Sales by Region: 2025-2030
3.3 Global HIV Therapy Global HIV Therapy Revenue by Region: 2019-2030
3.3.1 Global HIV Therapy Revenue by Region: 2019-2024
3.3.2 Global HIV Therapy Revenue by Region: 2025-2030
3.4 North America HIV Therapy Market Facts & Figures by Country
3.4.1 North America HIV Therapy Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America HIV Therapy Sales by Country (2019-2030)
3.4.3 North America HIV Therapy Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe HIV Therapy Market Facts & Figures by Country
3.5.1 Europe HIV Therapy Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe HIV Therapy Sales by Country (2019-2030)
3.5.3 Europe HIV Therapy Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific HIV Therapy Market Facts & Figures by Country
3.6.1 Asia Pacific HIV Therapy Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific HIV Therapy Sales by Country (2019-2030)
3.6.3 Asia Pacific HIV Therapy Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America HIV Therapy Market Facts & Figures by Country
3.7.1 Latin America HIV Therapy Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America HIV Therapy Sales by Country (2019-2030)
3.7.3 Latin America HIV Therapy Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa HIV Therapy Market Facts & Figures by Country
3.8.1 Middle East and Africa HIV Therapy Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa HIV Therapy Sales by Country (2019-2030)
3.8.3 Middle East and Africa HIV Therapy Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global HIV Therapy Sales by Type (2019-2030)
4.1.1 Global HIV Therapy Sales by Type (2019-2024)
4.1.2 Global HIV Therapy Sales by Type (2025-2030)
4.1.3 Global HIV Therapy Sales Market Share by Type (2019-2030)
4.2 Global HIV Therapy Revenue by Type (2019-2030)
4.2.1 Global HIV Therapy Revenue by Type (2019-2024)
4.2.2 Global HIV Therapy Revenue by Type (2025-2030)
4.2.3 Global HIV Therapy Revenue Market Share by Type (2019-2030)
4.3 Global HIV Therapy Price by Type (2019-2030)
5 Segment by Application
5.1 Global HIV Therapy Sales by Application (2019-2030)
5.1.1 Global HIV Therapy Sales by Application (2019-2024)
5.1.2 Global HIV Therapy Sales by Application (2025-2030)
5.1.3 Global HIV Therapy Sales Market Share by Application (2019-2030)
5.2 Global HIV Therapy Revenue by Application (2019-2030)
5.2.1 Global HIV Therapy Revenue by Application (2019-2024)
5.2.2 Global HIV Therapy Revenue by Application (2025-2030)
5.2.3 Global HIV Therapy Revenue Market Share by Application (2019-2030)
5.3 Global HIV Therapy Price by Application (2019-2030)
6 Key Companies Profiled
6.1 ViiV Healthcare
6.1.1 ViiV Healthcare Corporation Information
6.1.2 ViiV Healthcare Description and Business Overview
6.1.3 ViiV Healthcare HIV Therapy Sales, Revenue and Gross Margin (2019-2024)
6.1.4 ViiV Healthcare HIV Therapy Product Portfolio
6.1.5 ViiV Healthcare Recent Developments/Updates
6.2 Gilead Sciences, Inc.
6.2.1 Gilead Sciences, Inc. Corporation Information
6.2.2 Gilead Sciences, Inc. Description and Business Overview
6.2.3 Gilead Sciences, Inc. HIV Therapy Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Gilead Sciences, Inc. HIV Therapy Product Portfolio
6.2.5 Gilead Sciences, Inc. Recent Developments/Updates
6.3 GlaxoSmithKline Plc
6.3.1 GlaxoSmithKline Plc Corporation Information
6.3.2 GlaxoSmithKline Plc Description and Business Overview
6.3.3 GlaxoSmithKline Plc HIV Therapy Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GlaxoSmithKline Plc HIV Therapy Product Portfolio
6.3.5 GlaxoSmithKline Plc Recent Developments/Updates
6.4 Merck Sharp & Dohme Corp.
6.4.1 Merck Sharp & Dohme Corp. Corporation Information
6.4.2 Merck Sharp & Dohme Corp. Description and Business Overview
6.4.3 Merck Sharp & Dohme Corp. HIV Therapy Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Sharp & Dohme Corp. HIV Therapy Product Portfolio
6.4.5 Merck Sharp & Dohme Corp. Recent Developments/Updates
6.5 Bristol-Myers Squibb Company
6.5.1 Bristol-Myers Squibb Company Corporation Information
6.5.2 Bristol-Myers Squibb Company Description and Business Overview
6.5.3 Bristol-Myers Squibb Company HIV Therapy Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bristol-Myers Squibb Company HIV Therapy Product Portfolio
6.5.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.6 Janssen Pharmaceuticals, Inc.
6.6.1 Janssen Pharmaceuticals, Inc. Corporation Information
6.6.2 Janssen Pharmaceuticals, Inc. Description and Business Overview
6.6.3 Janssen Pharmaceuticals, Inc. HIV Therapy Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Janssen Pharmaceuticals, Inc. HIV Therapy Product Portfolio
6.6.5 Janssen Pharmaceuticals, Inc. Recent Developments/Updates
6.7 Boehringer Ingelheim International GmbH
6.6.1 Boehringer Ingelheim International GmbH Corporation Information
6.6.2 Boehringer Ingelheim International GmbH Description and Business Overview
6.6.3 Boehringer Ingelheim International GmbH HIV Therapy Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Boehringer Ingelheim International GmbH HIV Therapy Product Portfolio
6.7.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
6.8 AbbVie Inc.
6.8.1 AbbVie Inc. Corporation Information
6.8.2 AbbVie Inc. Description and Business Overview
6.8.3 AbbVie Inc. HIV Therapy Sales, Revenue and Gross Margin (2019-2024)
6.8.4 AbbVie Inc. HIV Therapy Product Portfolio
6.8.5 AbbVie Inc. Recent Developments/Updates
6.9 Genentech, Inc.
6.9.1 Genentech, Inc. Corporation Information
6.9.2 Genentech, Inc. Description and Business Overview
6.9.3 Genentech, Inc. HIV Therapy Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Genentech, Inc. HIV Therapy Product Portfolio
6.9.5 Genentech, Inc. Recent Developments/Updates
6.10 Mylan N.V.
6.10.1 Mylan N.V. Corporation Information
6.10.2 Mylan N.V. Description and Business Overview
6.10.3 Mylan N.V. HIV Therapy Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Mylan N.V. HIV Therapy Product Portfolio
6.10.5 Mylan N.V. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 HIV Therapy Industry Chain Analysis
7.2 HIV Therapy Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 HIV Therapy Production Mode & Process
7.4 HIV Therapy Sales and Marketing
7.4.1 HIV Therapy Sales Channels
7.4.2 HIV Therapy Distributors
7.5 HIV Therapy Customers
8 HIV Therapy Market Dynamics
8.1 HIV Therapy Industry Trends
8.2 HIV Therapy Market Drivers
8.3 HIV Therapy Market Challenges
8.4 HIV Therapy Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global HIV Therapy Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global HIV Therapy Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global HIV Therapy Market Competitive Situation by Manufacturers in 2023
Table 4. Global HIV Therapy Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global HIV Therapy Sales Market Share by Manufacturers (2019-2024)
Table 6. Global HIV Therapy Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global HIV Therapy Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market HIV Therapy Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of HIV Therapy, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of HIV Therapy, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of HIV Therapy, Product Type & Application
Table 12. Global Key Manufacturers of HIV Therapy, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global HIV Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Therapy as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global HIV Therapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global HIV Therapy Sales by Region (2019-2024) & (K Units)
Table 18. Global HIV Therapy Sales Market Share by Region (2019-2024)
Table 19. Global HIV Therapy Sales by Region (2025-2030) & (K Units)
Table 20. Global HIV Therapy Sales Market Share by Region (2025-2030)
Table 21. Global HIV Therapy Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global HIV Therapy Revenue Market Share by Region (2019-2024)
Table 23. Global HIV Therapy Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global HIV Therapy Revenue Market Share by Region (2025-2030)
Table 25. North America HIV Therapy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America HIV Therapy Sales by Country (2019-2024) & (K Units)
Table 27. North America HIV Therapy Sales by Country (2025-2030) & (K Units)
Table 28. North America HIV Therapy Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America HIV Therapy Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe HIV Therapy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe HIV Therapy Sales by Country (2019-2024) & (K Units)
Table 32. Europe HIV Therapy Sales by Country (2025-2030) & (K Units)
Table 33. Europe HIV Therapy Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe HIV Therapy Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific HIV Therapy Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific HIV Therapy Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific HIV Therapy Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific HIV Therapy Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific HIV Therapy Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America HIV Therapy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America HIV Therapy Sales by Country (2019-2024) & (K Units)
Table 42. Latin America HIV Therapy Sales by Country (2025-2030) & (K Units)
Table 43. Latin America HIV Therapy Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America HIV Therapy Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa HIV Therapy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa HIV Therapy Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa HIV Therapy Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa HIV Therapy Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa HIV Therapy Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global HIV Therapy Sales (K Units) by Type (2019-2024)
Table 51. Global HIV Therapy Sales (K Units) by Type (2025-2030)
Table 52. Global HIV Therapy Sales Market Share by Type (2019-2024)
Table 53. Global HIV Therapy Sales Market Share by Type (2025-2030)
Table 54. Global HIV Therapy Revenue (US$ Million) by Type (2019-2024)
Table 55. Global HIV Therapy Revenue (US$ Million) by Type (2025-2030)
Table 56. Global HIV Therapy Revenue Market Share by Type (2019-2024)
Table 57. Global HIV Therapy Revenue Market Share by Type (2025-2030)
Table 58. Global HIV Therapy Price (US$/Unit) by Type (2019-2024)
Table 59. Global HIV Therapy Price (US$/Unit) by Type (2025-2030)
Table 60. Global HIV Therapy Sales (K Units) by Application (2019-2024)
Table 61. Global HIV Therapy Sales (K Units) by Application (2025-2030)
Table 62. Global HIV Therapy Sales Market Share by Application (2019-2024)
Table 63. Global HIV Therapy Sales Market Share by Application (2025-2030)
Table 64. Global HIV Therapy Revenue (US$ Million) by Application (2019-2024)
Table 65. Global HIV Therapy Revenue (US$ Million) by Application (2025-2030)
Table 66. Global HIV Therapy Revenue Market Share by Application (2019-2024)
Table 67. Global HIV Therapy Revenue Market Share by Application (2025-2030)
Table 68. Global HIV Therapy Price (US$/Unit) by Application (2019-2024)
Table 69. Global HIV Therapy Price (US$/Unit) by Application (2025-2030)
Table 70. ViiV Healthcare Corporation Information
Table 71. ViiV Healthcare Description and Business Overview
Table 72. ViiV Healthcare HIV Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. ViiV Healthcare HIV Therapy Product
Table 74. ViiV Healthcare Recent Developments/Updates
Table 75. Gilead Sciences, Inc. Corporation Information
Table 76. Gilead Sciences, Inc. Description and Business Overview
Table 77. Gilead Sciences, Inc. HIV Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Gilead Sciences, Inc. HIV Therapy Product
Table 79. Gilead Sciences, Inc. Recent Developments/Updates
Table 80. GlaxoSmithKline Plc Corporation Information
Table 81. GlaxoSmithKline Plc Description and Business Overview
Table 82. GlaxoSmithKline Plc HIV Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. GlaxoSmithKline Plc HIV Therapy Product
Table 84. GlaxoSmithKline Plc Recent Developments/Updates
Table 85. Merck Sharp & Dohme Corp. Corporation Information
Table 86. Merck Sharp & Dohme Corp. Description and Business Overview
Table 87. Merck Sharp & Dohme Corp. HIV Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Merck Sharp & Dohme Corp. HIV Therapy Product
Table 89. Merck Sharp & Dohme Corp. Recent Developments/Updates
Table 90. Bristol-Myers Squibb Company Corporation Information
Table 91. Bristol-Myers Squibb Company Description and Business Overview
Table 92. Bristol-Myers Squibb Company HIV Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Bristol-Myers Squibb Company HIV Therapy Product
Table 94. Bristol-Myers Squibb Company Recent Developments/Updates
Table 95. Janssen Pharmaceuticals, Inc. Corporation Information
Table 96. Janssen Pharmaceuticals, Inc. Description and Business Overview
Table 97. Janssen Pharmaceuticals, Inc. HIV Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Janssen Pharmaceuticals, Inc. HIV Therapy Product
Table 99. Janssen Pharmaceuticals, Inc. Recent Developments/Updates
Table 100. Boehringer Ingelheim International GmbH Corporation Information
Table 101. Boehringer Ingelheim International GmbH Description and Business Overview
Table 102. Boehringer Ingelheim International GmbH HIV Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Boehringer Ingelheim International GmbH HIV Therapy Product
Table 104. Boehringer Ingelheim International GmbH Recent Developments/Updates
Table 105. AbbVie Inc. Corporation Information
Table 106. AbbVie Inc. Description and Business Overview
Table 107. AbbVie Inc. HIV Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. AbbVie Inc. HIV Therapy Product
Table 109. AbbVie Inc. Recent Developments/Updates
Table 110. Genentech, Inc. Corporation Information
Table 111. Genentech, Inc. Description and Business Overview
Table 112. Genentech, Inc. HIV Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Genentech, Inc. HIV Therapy Product
Table 114. Genentech, Inc. Recent Developments/Updates
Table 115. Mylan N.V. Corporation Information
Table 116. Mylan N.V. Description and Business Overview
Table 117. Mylan N.V. HIV Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Mylan N.V. HIV Therapy Product
Table 119. Mylan N.V. Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. HIV Therapy Distributors List
Table 123. HIV Therapy Customers List
Table 124. HIV Therapy Market Trends
Table 125. HIV Therapy Market Drivers
Table 126. HIV Therapy Market Challenges
Table 127. HIV Therapy Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of HIV Therapy
Figure 2. Global HIV Therapy Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global HIV Therapy Market Share by Type in 2023 & 2030
Figure 4. Integrase Inhibitors Product Picture
Figure 5. Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Product Picture
Figure 6. Combination HIV Medicines Product Picture
Figure 7. Others Product Picture
Figure 8. Global HIV Therapy Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global HIV Therapy Market Share by Application in 2023 & 2030
Figure 10. Hospital Pharmacies
Figure 11. Retail Pharmacies
Figure 12. Online Pharmacies
Figure 13. Others
Figure 14. Global HIV Therapy Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global HIV Therapy Market Size (2019-2030) & (US$ Million)
Figure 16. Global HIV Therapy Sales (2019-2030) & (K Units)
Figure 17. Global HIV Therapy Average Price (US$/Unit) & (2019-2030)
Figure 18. HIV Therapy Report Years Considered
Figure 19. HIV Therapy Sales Share by Manufacturers in 2023
Figure 20. Global HIV Therapy Revenue Share by Manufacturers in 2023
Figure 21. The Global 5 and 10 Largest HIV Therapy Players: Market Share by Revenue in 2023
Figure 22. HIV Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 23. Global HIV Therapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 24. North America HIV Therapy Sales Market Share by Country (2019-2030)
Figure 25. North America HIV Therapy Revenue Market Share by Country (2019-2030)
Figure 26. U.S. HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Canada HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Europe HIV Therapy Sales Market Share by Country (2019-2030)
Figure 29. Europe HIV Therapy Revenue Market Share by Country (2019-2030)
Figure 30. Germany HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. France HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. U.K. HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Italy HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Russia HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Asia Pacific HIV Therapy Sales Market Share by Region (2019-2030)
Figure 36. Asia Pacific HIV Therapy Revenue Market Share by Region (2019-2030)
Figure 37. China HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Japan HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. South Korea HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. India HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Australia HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Taiwan HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Indonesia HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Thailand HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Malaysia HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Philippines HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Latin America HIV Therapy Sales Market Share by Country (2019-2030)
Figure 48. Latin America HIV Therapy Revenue Market Share by Country (2019-2030)
Figure 49. Mexico HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Brazil HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Argentina HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Middle East & Africa HIV Therapy Sales Market Share by Country (2019-2030)
Figure 53. Middle East & Africa HIV Therapy Revenue Market Share by Country (2019-2030)
Figure 54. Turkey HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Saudi Arabia HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. U.A.E HIV Therapy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. Global Sales Market Share of HIV Therapy by Type (2019-2030)
Figure 58. Global Revenue Market Share of HIV Therapy by Type (2019-2030)
Figure 59. Global HIV Therapy Price (US$/Unit) by Type (2019-2030)
Figure 60. Global Sales Market Share of HIV Therapy by Application (2019-2030)
Figure 61. Global Revenue Market Share of HIV Therapy by Application (2019-2030)
Figure 62. Global HIV Therapy Price (US$/Unit) by Application (2019-2030)
Figure 63. HIV Therapy Value Chain
Figure 64. HIV Therapy Production Process
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Distributors Profiles
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
